Careium (CARE) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
5 Jun, 2025Executive summary
Growth achieved in all markets except Sweden, which was impacted by contract delays and lower upfront leasing revenue.
Notable wins include a major stationary alarm order in France, first sales in Spain, and a 12-year Norwegian contract valued at SEK 24 million annually.
Margins remained strong, supported by a one-time UK revenue recognition effect.
Profit for the period dropped 47.4% to SEK 7.5 million, mainly due to negative currency effects and higher costs.
B2C and assisted living frameworks identified as key future growth areas.
Financial highlights
Organic sales declined 1.6% year-over-year (2.3% adjusted for currency); net sales SEK 207.4 million.
Service sales rose 3.4% to SEK 160.3m, product sales fell 15.5% to SEK 47.1m.
Gross margin improved to 44.5% from 42.9%, aided by a one-time UK effect.
EBITDA was SEK 33.6m (margin 16.2%), EBIT SEK 16.6m (margin 8.0%), both down year-over-year due to higher costs.
Cash flow from operations was SEK 19.3m, free cash flow at SEK -4.4m, impacted by higher taxes and investments.
Outlook and guidance
Net sales, profitability, and free cash flow before acquisitions expected to increase in 2025 versus 2024.
Softer first half anticipated due to Swedish market awaiting new framework; stronger second half expected.
Focus on B2C expansion, assisted living frameworks, and targeted acquisitions.
Latest events from Careium
- Q4 2025 delivered modest sales growth, lower EBIT, and stronger cash flow amid margin pressure.CARE
Q4 202516 Feb 2026 - Aging demographics fuel growth in care tech, with innovation and recurring revenue driving strategy.CARE
ABGSC Investor Days12 Jan 2026 - Q3 2025 delivered 6% sales growth, higher margins, and strong product sales despite one-off costs.CARE
Q3 202524 Oct 2025 - Sales fell but gross margin and cash flow improved; H2 growth expected from new contracts.CARE
Q2 202511 Jul 2025 - Sales dropped 7.2%, but strong margins and new platforms support growth targets.CARE
Q3 202413 Jun 2025 - Q2 sales and EBIT surged, driven by EU market gains despite UK/Nordic delays.CARE
Q2 202413 Jun 2025 - Strong sales and profit growth, with 2025 set for further expansion and innovation.CARE
Q4 20245 Jun 2025